Berkeley Lab and Genentech are collaborating to make the next generation of lipid nanoparticles (LNPs), the drug delivery technology used in the COVID-19 vaccines. With their combined expertise in structural biology and pharmaceutical science, the team is designing LNPs that can precisely deliver vaccines and therapeutics to target tissues while improving the product’s shelf life and duration of action.
Proteins Designed Using Reinforcement Learning Characterized on SIBYLS Beamline
The SIBYLS beamline at the Advanced Light Source was used to characterize proteins dreamt up by a reinforcement learning algorithm. The algorithm, developed by researchers in David Baker’s lab at the University of Washington, is powered by the machine learning strategy behind computer programs capable of defeating top human players at board games like chess and go. The advance could create a pathway to greater control when designing therapeutic proteins, vaccines, and other molecules.
Gemini Beamline Banks First Protein Structure
A protein structure obtained at Beamline 2.0.1 (“Gemini”) at the Advanced Light Source (ALS) has recently been published in the literature and deposited into the Protein Data Bank—two significant firsts for this beamline. The structure helped provide new insights into the molecular mechanisms involved in triggering certain inflammatory diseases. This milestone, which utilized Gemini’s capacity to target crystals smaller than 20 microns, was almost a decade in the making. Simon Morton, now a semi-retired staff scientist at ALS, and Corie Ralston, facility director at the Molecular Foundry and a staff scientist in the Molecular Biophysics and Integrated Bioimaging Division (MBIB), helped bring the microfocus beamline to the Berkeley Center for Structural Biology (BCSB) in 2014. Beamline operations are now led by Marc Allaire, a biophysicist staff scientist in MBIB and head of the BCSB.
Read More in the Berkeley Lab News Center.
Anthony Rozales, Beamline Runner
For Anthony Rozales, his shift overseeing the protein crystallography beamlines begins before the sun rises. While some might find the early mornings grueling, for him it’s ideal. Most days, after his shift ends and he makes it home, Rozales usually turns right around and leaves again, this time on foot.
Structural Imaging at ALS Yields New Insights into DNA Repair Enzyme
PARP1 is an enzyme that senses DNA damage and sends a cellular signal to carry out repair. It has been found to be upregulated in several carcinomas and inhibiting its activity has been shown to repress tumor growth and metastasis. PARP1 has also emerged as a promising therapeutic target for Alzheimer and Parkinson diseases, where attenuating the enzyme’s hyperactivity can help cells survive. To better understand the regions of PARP1 that various inhibitors attack, an international team of researchers captured the first snapshot of the enzyme in the active state it adopts after detecting DNA damage.
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 17
- Next Page »
Was this page useful?
Send
